FDA Accepts Mylan-Biocon Pegfilgrastim Biosimilar Application
AbbVie, Novartis Unhappy With FDA Guidance on Naming Biologics and Biosimilars
Herceptin, Rituxan Biosimilars Might Soon Reach Oncologists in Europe
Efficacy and Safety of Anti-TNF-alpha Biosimilars Comparable to Reference Drugs in RA and AS
Bevacizumab Biosimilar Could Address Global Barriers to Access
Does a Drug's Mechanism Regulate Retention by Patients With Psoriasis?
New Player in the Biosimilars Game: Aurobindo Pharma
Legal and Regulatory Decisions Likely to Drive Biosimilar Approvals in 2017
Will 2017 Change the Fate of Biosimilars? An Update From the CBI Summit
Biosimilar Knowledge Gaps Identified Among US Specialty Physicians
How Will Pfizer's Infliximab Biosimilar Compete With Remicade?
ECCO Supports Switching From Remicade to Biosimilar Infliximab for IBD Patients
EMA Pilot Will Provide Tailored Advice to Biosimilar Developers, Similar to FDA Process
Treating Rheumatoid Arthritis With Biologic Medications: A Quick Take
The FDA vs the EC: Two Very Different Ways to Address Biosimilar Education
EMA Concerns Prompt Sandoz to Withdraw Neulasta Biosimilar Application
What Influences Physicians' Decisions About Patient Suitability for Biosimilar Infliximab?
Three Insulin Makers Face Class-Action Lawsuit on Price Fixing
FDA Filing of Sandoz's Humira Biosimilar Delayed
FDA Hiring Freeze Could Slow Down Biosimilar Approval Process
Novartis: The Company at the Forefront of Biosimilar Development
EMA Committee Recommends Approval of Amgen's Adalimumab Biosimilar
Novartis's Enbrel Biosimilar Marketing Delayed
The Supreme Court: Amgen v. Sandoz Briefing Schedule
Are Biosimilars Potential Market Disruptors?
EMA Launching Pilot to Support Biosimilars Development
FDA Releases Draft Guidance on Biosimilar Interchangeability
Biosimilars for Psoriasis: Spain's Dermatologists Weigh In
Instagram Pages
Here you can access stories featured on our instagram page. Want more biosimilar news? Sign up for our weekly newsletter, delivered to your inbox every Wednesday here.
FDA Extends NDA Review Period for New RA Treatment Expected to Compete with Humira
